
Monte Rosa Therapeutics is seeking a contractor (6 months) with the experience to implement and run complex cellular assays. This position is a key role in the pivotal team responsible for Automation and Screening Technologies & hits-to-leads support for Monte Rosa’s diverse pipeline. The ideal candidate will be able to help evolve Monte Rosa’s hit identification and hits-to-leads endeavors through embracing novel assay technologies, enhancing overall processes and actively drive internal and external partnerships.

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.